Evaluation of anaphylaxis risk by skin testing with Covid-19 messenger RNA vaccines on patients with anaphylaxis
Anapylaxis Risk Analysis via Skin Testing with Covid-19 Vaccines Vaccination has been found to be effective in reducing the risks of infection of severe acute respiratory syndrome coronavirus and severe coronavirus disease 2019 (COVID-19) outcomes. In the United States, Pfizer-BioNTech and Moderna COVID-19 vaccines (aka the messenger RNA [mRNA] vaccines) have been used …